News

Show
news from

Cambridge Epigenetix Names Peter Fromen as Chief Executive Officer

Freeline Initiates Dosing of Second Cohort in B-LIEVE Dose Confirmation Trial of FLT180a in Hemophilia B

Autolus Therapeutics Presents Clinical Data Updates at the European Hematology Association Congress

Anaveon Announces FDA Safe to proceed letter for Investigational New Drug (IND) Application for its no-alpha IL-2 agonist, ANV419

Freeline Receives Nasdaq Deficiency Notice Regarding Minimum Bid Price Requirement

Autolus Therapeutics to Participate in the Jefferies Healthcare Conference, being held in New York from June 8 – 10, 2022

Load more

Search